Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (1057)	6/20/1999 10:21:00 PM
From: LLCF	Respond to of 3202

< I took a bunch of notes and will produce them one of these nights> Can't wait... thanks for all your valuable input on INCY... any comment on this [anyone?]: Message 10198938 Although I added nicely to my position below $20, I'm thinking about tripling up on my INCY at these levels. I don't want to wait too much longer seeing that the street may start looking past the "stepped up expenses in '99" soon and start looking forward to future earnings. A surprise contract or two in the 3rd quarter could send this thing rocking again. DAK

To: Rocketman who wrote (1057)	6/24/1999 11:28:00 AM
From: LLCF	Respond to of 3202

LION bioscience an Bayer enter $100m research alliance- New LION Subsid to develope & apply infomation technology of acceleratingdrug discovery linking researchers and information through "i-biology". blah,blah, five-year alliance to increase the speed and effic of bayer'sgene and drug discovery efforts through the use of an information technology-based managment system. Under the alliance, which is based on the formation of a new research subsid, LION will develop and apply new IT-systames for ultra high throughput ID and validation of new drug targets, gene expression markers and SNP's. Bayer's investment is estimated to be worth $100m... this figure includes upfront equity stake in LION AG as well as fees for use of LION's existing IT-systems, research and set up costs for the new sbsid. and royalties on drugs developed with gene targets identified and validated at the subsid. Over the next 5 yrs LION bioscience Research Inc. (LBRI), the wholly owned Cambridge Mass subsid of LION AG, shall deliver to Bayer 500 new target genes, 70 new annotations on existing Bayer owned gene targets and an undiscloed number of gene expression markers and SNP's. All targets will be identified and validaated and LBRI using the aformentioned novel IT-systems. The resulting info will be globally accessible to Bayer's scientists via and Intranet system. This interdisciplinary approach for the integration of data, information, hard and software as well as the direct involement of scientists in drug discovery is called i-biology. LBRI will be run by Dr. Reinhard Schneider, a co-founder of LION AG. A team of more than 20 IT-systmes developers, software engineers and bioinfomaticieans shall be hired. Bayer will receive exclusive rights to targets and markers identified by LBRI. LION will retain rights on all IT and software developments achieved at the subsid. Bayer will recieve unlimited, non-exclusive access to the softweare and IT-developments of LBRI. These systems will be impemented at Bayerss worldwide researach sites. "Most innovations in the life sciences are coming from highly specialized companies which are located in teh U.S. I am personally highly delighted that inthes case we hae found a competent partner in Germany. This is proof that the efforts to develop this country into a leading place for biotech innovations are bearing fruit." DAK

To: Rocketman who wrote (1057)	6/29/1999 4:46:00 PM
From: RCMac	Read Replies (5) \| Respond to of 3202

New INCY proteomics database program announced today biz.yahoo.com Tuesday June 29, 4:01 pm Eastern Time Company Press Release SOURCE: Oxford GlycoSciences plc and Incyte Pharmaceuticals, Inc. Incyte and Oxford GlycoSciences Announce Launch of Toxicology and Pharmacology Proteomics Database OSLO, Norway, June 29 /PRNewswire/ -- Today, Oxford GlycoSciences plc, Oxford, England (London: OGS), and Incyte Pharmaceuticals, Inc, Palo Alto, CA (Nasdaq: INCY - news) at the Eurotox'99 conference in Oslo, Norway, announced the launch of a new program -- PharmacoProgram(TM) -- focused on the application of proteomics technology to study compound efficacy and safety. The PharmacoProgram will enhance the drug development process by better defining the molecular basis of drug action. The Eurotox'99 meeting was also used to announce the European launch of the powerful new protein analysis software package -- LifeProt(TM). Pharmaceutical partners will be able to purchase multi-year access to the PharmacoProgram. Partners will have access to the expanding, non-exclusive database content and will also receive the LifeProt software. In addition, partners will be able to purchase a pre-determined level of customer-driven gene and expression analysis experiments. The PharmacoProgram is the second of three programs to result from the new integrated gene and protein expression technology platform. It provides new ways to understand molecular-level toxicology and pharmacology and facilitates lead compound optimization in drug development and discovery. The joint Incyte and OGS proteomic project integrates genomic and proteomic technologies, creating the world's first integrated gene and protein expression technology platform. This platform allows pharmaceutical companies to: oDiscover novel protein and novel peptide sequences.oIdentify protein cellular and subcellular locations.oAssess how messenger RNA expression levels correlate to protein expression levels. o Assign function through analysis of co-expression and subcellular localization. The two other proteomics programs are: -- PathoProgram (available since April, 1999). It provides expression data from thousands of uniquely identified and characterized proteins from Staphylococcus aureus and Candida albicans to facilitate the discovery and selection of new anti-infective drugs. -- LifeProgram will be launched in the coming weeks. It facilitates the identification, selection, and validation of new drug screening targets and protein therapeutics relevant to human diseases. LifeProgram data includes several thousand uniquely identified and characterized proteins from a range of human systems. The LifeProt software is a joint software product developed by Incyte and OGS for the management of proteomics data. Together with Incyte's LifeArray(TM) and LifeTools(TM) software, LifeProt provides a unique platform for integrating genomic RNA expression data and protein expression data in a single environment. LifeProt will give researchers these capabilities: oStore, retrieve, mine, and subset protein data.oResearch specific proteins in-depth.oMap proteins to other types of Incyte data.oInterface directly with other Incyte databases and analysis tools.oIdentify potential targets for further research. ''This new generation of databases will accelerate drug discovery and development programs by improving the process of target selection and lead optimization,'' states Randy Scott, President and CSO at Incyte. ''With LifeProt, our protein expression databases and technology have the scale, sensitivity, and reproducibility to help our pharmaceutical partners find and validate new therapeutic targets, undertake real-time drug mechanistic studies, and evaluate potential toxicology much earlier in the drug discovery process,'' says Michael Kranda, CEO of OGS. ''We are extremely pleased with the progress that Incyte and OGS have made in developing these products. The power of integrating our respective expression-based technologies in a single platform through the LifeProt software is truly impressive. We are equally excited that our pharmaceutical partners have expressed such an early level of interest in these products.'' Incyte Pharmaceuticals, Inc. is a leading provider . . . . [etc.] Oxford GlycoSciences (OGS) is an established biotechnology company founded by Oxford University to identify and analyze glycoproteins. OGS is today recognized as a world leader in proteomics technology . . . . . [etc.]